New Age Alpha Advisors LLC Takes $665,000 Position in Johnson & Johnson (NYSE:JNJ)

New Age Alpha Advisors LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 4,597 shares of the company's stock, valued at approximately $665,000.

A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of Johnson & Johnson by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after acquiring an additional 1,772,706 shares in the last quarter. State Street Corp raised its position in Johnson & Johnson by 0.9% during the 3rd quarter. State Street Corp now owns 134,245,811 shares of the company's stock valued at $21,755,874,000 after purchasing an additional 1,154,088 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 56,106,884 shares of the company's stock worth $9,064,149,000 after buying an additional 1,004,763 shares during the period. Norges Bank bought a new position in shares of Johnson & Johnson during the 4th quarter worth $4,390,037,000. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Johnson & Johnson by 3.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 18,187,082 shares of the company's stock valued at $2,630,216,000 after buying an additional 547,714 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

JNJ has been the topic of several recent research reports. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Royal Bank of Canada reiterated an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Stifel Nicolaus dropped their target price on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research report on Thursday, January 23rd. Finally, Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $171.33.

Insider Activity

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

JNJ stock traded down $6.79 during trading on Friday, reaching $153.03. The company had a trading volume of 16,594,687 shares, compared to its average volume of 7,796,010. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a market cap of $368.77 billion, a price-to-earnings ratio of 23.01, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The firm has a 50-day simple moving average of $159.75 and a 200-day simple moving average of $155.91.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business's quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the company earned $2.29 earnings per share. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.